CTLA4 and melanoma: The U.S. FDA first approved ipilimumab as an immune checkpoint inhibitor for treating advanced melanoma.379 It is a fully human monoclonal antibody that binds to CTLA-4 and inhibits its interaction with CD80/CD86.